Avoro Capital Advisors LLC - Q4 2021 holdings

$5.88 Billion is the total value of Avoro Capital Advisors LLC's 41 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 15.8% .

 Value Shares↓ Weighting
HZNP BuyHORIZON THERAPEUTICS PLC$1,001,629,000
+1.6%
9,295,000
+3.3%
17.05%
+10.1%
MRTX BuyMIRATI THERAPEUTICS INC$744,452,000
-15.8%
5,075,000
+1.5%
12.67%
-8.8%
UTHR BuyUNITED THERAPEUTICS CORP$655,803,000
+18.4%
3,035,000
+1.2%
11.16%
+28.3%
APLS BuyAPELLIS PHARMACEUTICALS INC$404,507,000
+145.5%
8,555,555
+71.1%
6.88%
+165.9%
ARGX BuyARGENX SEsponsored adr$337,933,000
+18.2%
965,000
+2.0%
5.75%
+28.1%
SRPT BuySAREPTA THERAPEUTICS INC$281,406,000
+21.7%
3,125,000
+25.0%
4.79%
+31.9%
ASND BuyASCENDIS PHARMAsponsored adr$269,060,000
-14.7%
2,000,000
+1.0%
4.58%
-7.6%
BMRN BuyBIOMARIN PHARMACEUTICAL INC$247,380,000
+70.7%
2,800,000
+49.3%
4.21%
+85.0%
FOLD BuyAMICUS THERAPEUTICS INC$213,675,000
+26.6%
18,500,000
+4.6%
3.64%
+37.1%
ALNY BuyALNYLAM PHARMACEUTICALS INC$182,299,000
+13.6%
1,075,000
+26.5%
3.10%
+23.1%
IOVA BuyIOVANCE BIOTHERAPEUTICS INC$165,606,000
-21.0%
8,675,000
+2.1%
2.82%
-14.4%
XENE BuyXENON PHARMACEUTICALS INC$155,731,000
+179.2%
4,985,000
+36.6%
2.65%
+202.5%
ISEE BuyIVERIC BIO INC$121,220,000
+5.1%
7,250,000
+2.1%
2.06%
+13.9%
XBI NewSPDR SERIES TRUST - S&P BIOTECHetf$117,558,0001,050,000
+100.0%
2.00%
SNDX BuySYNDAX PHARMACEUTICALS INC$47,611,000
+61.3%
2,175,000
+40.8%
0.81%
+74.6%
PRAX BuyPRAXIS PRECISION MEDICINES INC$35,066,000
+18.5%
1,780,000
+11.2%
0.60%
+28.4%
DSGN BuyDESIGN THERAPEUTICS INC$35,029,000
+62.4%
1,636,100
+11.4%
0.60%
+75.8%
KYMR BuyKYMERA THERAPEUTICS INC$34,920,000
+30.4%
550,000
+20.7%
0.59%
+41.1%
KRYS NewKRYSTAL BIOTECH INC$33,226,000475,000
+100.0%
0.56%
RNA BuyAVIDITY BIOSCIENCES INC$29,237,000
+3.2%
1,230,000
+7.0%
0.50%
+11.9%
NewIO BIOTECH INC$10,243,0002,055,883
+100.0%
0.17%
SRPT BuySAREPTA THERAPEUTICS INCcall$2,910,000
+32.6%
300,000
+50.0%
0.05%
+47.1%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-02-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
AMICUS THERAPEUTICS INC36Q3 202317.9%
MIRATI THERAPEUTICS INC.35Q3 202317.2%
BIOMARIN PHARMACEUTICAL INC31Q3 20238.0%
SAREPTA THERAPUTICS INC28Q3 202314.8%
ASCENDIS PHARMA28Q3 20239.1%
ARGENX SE26Q3 20239.5%
IOVANCE BIOTHERAPEUTICS INC26Q3 20239.1%
FENNEC PHARMACEUTICALS INC25Q3 20230.4%
MADRIGAL PHARMACEUTICALS INC22Q3 20237.2%
XENON PHARMACEUTICALS INC22Q3 20233.3%

View Avoro Capital Advisors LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Avoro Capital Advisors LLC Q4 2021 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Adverum Biotechnologies, Inc.Sold outFebruary 14, 202300.0%
DICE Therapeutics, Inc.February 14, 20232,525,5555.3%
IOVANCE BIOTHERAPEUTICS, INC.February 14, 20237,020,0004.4%
IVERIC bio, Inc.February 14, 20236,750,0005.0%
Kura Oncology, Inc.February 14, 20233,105,0004.5%
Aadi Bioscience, Inc.September 26, 20222,849,40211.7%
ARENA PHARMACEUTICALS INCFebruary 11, 20221,235,0002.0%
AVADEL PHARMACEUTICALS PLCFebruary 11, 20221,670,0002.9%
FENNEC PHARMACEUTICALS INC.February 11, 20221,200,0004.6%
POINT Biopharma Global Inc.Sold outFebruary 11, 202200.0%

View Avoro Capital Advisors LLC's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-05-15
SC 13G/A2024-04-23
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Avoro Capital Advisors LLC's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported total value is incorrect (5875771000.0 != 5875773000.0)

Export Avoro Capital Advisors LLC's holdings